NCT05468190

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Status unknown Phase 1 Last updated 18 August 2023

What this trial tests

Phase 1 trial testing CD70 CAR-T cells in Metastatic Tumor in 48 participants. Status unknown.

Timeline

17 July 2022

Primary endpoint
17 July 2024

17 July 2025

Quick facts

Lead sponsor	Chongqing Precision Biotech Co., Ltd
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	17 July 2022
Primary completion	17 July 2024
Estimated completion	17 July 2025
Sites	1 location across China

Drugs / interventions tested

• CD70 CAR-T cells
• CD70 CAR-T cells

Conditions studied

• Metastatic Tumor — all drugs for Metastatic Tumor →
• Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
• Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
• Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Chongqing Precision Biotech Co., Ltd — full company profile →

Who can join

18 and older, any sex, with Metastatic Tumor or Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As a phase I clinical research，this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment.
   Yan T, Zhu L, Chen J. · · 2023 · cited 132× · PMID 36707873 · DOI 10.1186/s40164-023-00373-7
2. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
   Meng L, Collier KA, Wang P, Li Z, et al · · 2023 · cited 48× · PMID 38201238 · DOI 10.3390/cells13010034
3. Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
   Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
4. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
   Cutri-French C, Nasioudis D, George E, Tanyi JL. · · 2024 · cited 23× · PMID 38667465 · DOI 10.3390/diagnostics14080819
5. Cancer stem cells: a target for overcoming therapeutic resistance and relapse.
   Zhang S, Yang R, Ouyang Y, Shen Y, et al · · 2024 · cited 20× · PMID 38164743 · DOI 10.20892/j.issn.2095-3941.2023.0333
6. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
   Qin Y, Xu G. · · 2022 · cited 18× · PMID 36569859 · DOI 10.3389/fimmu.2022.1053120
7. Advances and obstacles of T cell-based immunotherapy in gynecological malignancies.
   Zhao X, Ran J, Li S, Chen J. · · 2025 · cited 14× · PMID 40713697 · DOI 10.1186/s12943-025-02411-w
8. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
   Holtermann A, Gislon M, Angele M, Subklewe M, et al · · 2024 · cited 13× · PMID 39080180 · DOI 10.1007/s40259-024-00669-y